Price$2.71-0.31 (-10.26%)
2026-05-212026-08-25
News · 26 weeks27+200%
2026-03-012026-08-23
Mix1290d
- Other6(50%)
- SEC Filings3(25%)
- Insider1(8%)
- Analyst1(8%)
- Offering1(8%)
Latest news
25 items- PRNkarta Reports Second Quarter 2026 Financial Results and Corporate HighlightsEnrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026Cash balance of $243.2 million on June 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. "Expanding access to NKX
- SECSEC Form 10-Q filed by Nkarta Inc.10-Q - Nkarta, Inc. (0001787400) (Filer)
- SECNkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nkarta, Inc. (0001787400) (Filer)
- PRCyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product DevelopmentParis, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory AffairsCéline Breda joins as VP, Chemistry, Manufacturing and Controls (CMC) Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics ("Cyllene Tx"), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve as Chair of the Audit Committee. The company has also strengthened its leadership team with two key additions. Clara Cambon-Thiebaud joins as Vice Pres
- PRA Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsIssued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications expanding beyond oncology.USA News Group News CommentaryNEW YORK, June 30, 2026 /CNW/ -- Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a recent update from GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company built around its proprietary natural
- PRNkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceSOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in next week’s H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases. A simultaneous webcast of the discussion will be available on the investors section of Nkarta’s website, and a replay will be archived on the website
- ANALYSTTD Cowen initiated coverage on NkartaTD Cowen initiated coverage of Nkarta with a rating of Buy
- INSIDERChief Executive Officer Hastings Paul J sold $4,813 worth of shares (1,776 units at $2.71), decreasing direct ownership by 0.45% to 390,247 units (SEC Form 4) to cover taxes4 - Nkarta, Inc. (0001787400) (Issuer)
- PRAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. But T-cell therapies also carry hard limits: they can be brutally toxic, they are often manufactured one p
- SECNkarta Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nkarta, Inc. (0001787400) (Filer)
- PRThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, Inc. (NASDAQ:GTBP) has now advanced three TriKE® candidates into the clinic over time --- GTB-3550, GTB-3650 and GTB-5550 --- though its curr
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nkarta Inc.SCHEDULE 13D/A - Nkarta, Inc. (0001787400) (Subject)
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
- SECSEC Form 10-Q filed by Nkarta Inc.10-Q - Nkarta, Inc. (0001787400) (Filer)
- SECNkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nkarta, Inc. (0001787400) (Filer)
- PRNkarta Reports First Quarter 2026 Financial Results and Corporate HighlightsEnrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026Cash balance of $266.7 million on March 31, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune di
- SECSEC Form DEFA14A filed by Nkarta Inc.DEFA14A - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form DEF 14A filed by Nkarta Inc.DEF 14A - Nkarta, Inc. (0001787400) (Filer)
- PRNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersExpanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) with initial data expected to be presented at a medical meeting this year SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1
- PRNkarta to Participate in Needham Virtual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference. At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, "Cell Therapy in Autoimmune: State of the Art and What Comes Next." Later that afternoon, Nkarta President Nadir Mahmood will participate in a 3:45 p.m ET fireside chat to share updates on the company's investigational CAR-NK cell therapy to treat B cell-mediated auto
- SECSEC Form EFFECT filed by Nkarta Inc.EFFECT - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form 424B5 filed by Nkarta Inc.424B5 - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form S-3 filed by Nkarta Inc.S-3 - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form 10-K filed by Nkarta Inc.10-K - Nkarta, Inc. (0001787400) (Filer)
NKTX FAQ
7 questionsWhat does Nkarta Inc. do?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which...Where does NKTX stock trade?
Nkarta Inc. (NKTX) is listed on NASDAQ.What sector and industry is NKTX in?
Nkarta Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nkarta Inc. go public?
Nkarta Inc. (NKTX) completed its IPO in 2020.What are analysts saying about NKTX?
Nkarta Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-06-23. Recent price targets range from $1400.00 to $2600.00.What companies are similar to NKTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NKTX side-by-side with any of them on Quantisnow.How can I track NKTX on Quantisnow?
Quantisnow aggregates Nkarta Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NKTX to receive live email and push alerts on every new disclosure.